Treatment of intermediate and advanced stage Hodgkin's disease with modified baseline BEACOPP regimen: a Hellenic Co-operative Oncology Group StudyECONOMOPOULOS, T; FOUNTZILAS, G; DIMOPOULOS, M. A et al.European journal of haematology. 2003, Vol 71, Num 4, pp 257-262, issn 0902-4441, 6 p.Article

FDG―PET for assessment of early treatment response after four cycles of chemotherapy in patients with advanced-stage Hodgkin's lymphoma has a high negative predictive valueMARKOVA, J; KOBE, C; SKOPALOVA, M et al.Annals of oncology. 2009, Vol 20, Num 7, pp 1270-1274, issn 0923-7534, 5 p.Article

Hodgkin lymphomaGOBBI, Paolo G; FERRERI, Andres J. M; PONZONI, Maurilio et al.Critical reviews in oncology/hematology. 2013, Vol 85, Num 2, pp 216-236, issn 1040-8428, 21 p.Article

A prospectively randomized trial carried out by the German Hodgkin Study Group (GHSG) for elderly patients with advanced Hodgkin's disease comparing BEACOPP baseline and COPP-ABVD (study HD9_elderly)BALLOVA, V; RÜFFER, J.-U; EICH, H. T et al.Annals of oncology. 2005, Vol 16, Num 1, pp 124-131, issn 0923-7534, 8 p.Article

Sexual quality of life in Hodgkin Lymphoma: a longitudinal analysis by the German Hodgkin Study GroupBEHRINGER, K; MÜLLER, H; FUCHS, M et al.British journal of cancer. 2013, Vol 108, Num 1, pp 49-57, issn 0007-0920, 9 p.Article

Early chemotherapy intensification with BEACOPP in advanced-stage Hodgkin lymphoma patients with a interim-PET positive after two ABVD coursesGALLAMINI, Andrea; PATTI, Caterina; SORASIO, Roberto et al.British journal of haematology. 2011, Vol 152, Num 5, pp 551-560, issn 0007-1048, 10 p.Article

Treatment of Hodgkin's disease : Results and current concepts of the German Hodgkin's Lymphoma Study GroupSIEBER, M; ENGERT, A; DIEHL, V et al.Annals of oncology. 2000, Vol 11, pp 81-85, issn 0923-7534, SUP1Conference Paper

Dose-escalation study for the treatment of Hodgkin's diseaseDIEHL, V.Annals of hematology (Print). 1993, Vol 66, Num 3, pp 139-140, issn 0939-5555Conference Paper

Acute hematologic toxicity and practicability of dose-intensified BEACOPP chemotherapy for advanced stage Hodgkin's diseaseENGEL, C; LOEFFLER, M; SCHMITZ, S et al.Annals of oncology. 2000, Vol 11, Num 9, pp 1105-1114, issn 0923-7534Article

Impact of first- and second-line treatment for Hodgkin's lymphoma on the incidence of AML/MDS and NHL—experience of the German Hodgkin's Lymphoma Study Group analyzed by a parametric model of carcinogenesisSCHOLZ, M; ENGERT, A; FRANKLIN, J et al.Annals of oncology. 2011, Vol 22, Num 3, pp 681-688, issn 0923-7534, 8 p.Article

Moderate dose escalation for advanced stage Hodgkin's disease using the bleomycin, etoposide, adriamycin, cyclophosphamide, vincristine, procarbazine, and prednisone scheme and adjuvant radiotherapy : A study of the German Hodgkin's lymphoma study groupTESCH, H; DIEHL, V; SCHWIEDER, G et al.Blood. 1998, Vol 92, Num 12, pp 4560-4567, issn 0006-4971Article

14-Day variant of the bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone regimen in advanced-stage Hodgkin's lymphoma: Results of a pilot study of the German Hodgkin's lymphoma study GroupSIEBER, M; BREDENFELD, H; SOEKLER, M et al.Journal of clinical oncology. 2003, Vol 21, Num 9, pp 1734-1739, issn 0732-183X, 6 p.Article